Enanta Pharmaceuticals Inc (ENTA) stock
ENTANasdaqPharmaceutical PreparationsFiscal year ends September 30
Financials through Q3 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026Score 2/3018% above fair value
$10.99−0.21 (-1.87%)
Close on Nov 13, 2026Market cap $320.09MP/E –Yield –
Enanta Pharmaceuticals cash
Cash and short-term investments held at the end of each period.
Enanta Pharmaceuticals's cash was $189.51M at Jun 30, 2026. For fiscal 2025 it was $188.86M, down 23.9% from the year before. Over ten years it grew 2.7% a year on average. The highest annual figure on record is $386.65M in fiscal 2020.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $188.86M | -23.9% |
| FY2024 | Sep 30, 2024 | $248.19M | -32.9% |
| FY2023 | Sep 30, 2023 | $369.91M | +48.4% |
| FY2022 | Sep 30, 2022 | $249.23M | +2.1% |
| FY2021 | Sep 30, 2021 | $244.00M | -36.9% |
| FY2020 | Sep 30, 2020 | $386.65M | +15.3% |
| FY2019 | Sep 30, 2019 | $335.24M | +8.6% |
| FY2018 | Sep 30, 2018 | $308.73M | +38.0% |
| FY2017 | Sep 30, 2017 | $223.67M | +1249.3% |
| FY2016 | Sep 30, 2016 | $16.58M | -88.6% |
| FY2015 | Sep 30, 2015 | $145.21M | +60.0% |
| FY2014 | Sep 30, 2014 | $90.76M | -10.6% |
| FY2013 | Sep 30, 2013 | $101.48M | +131.9% |
| FY2012 | Sep 30, 2012 | $43.76M | +540.1% |
| FY2011 | Sep 30, 2011 | $6.84M | +1367.2% |
| FY2010 | Sep 30, 2010 | $466.00K | – |
Quarterly cash
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026CQ2 2026 | Jun 30, 2026 | $189.51M | -7.2% |
| Q2 FY2026CQ1 2026 | Mar 31, 2026 | $163.77M | -24.4% |
| Q1 FY2026CQ4 2025 | Dec 31, 2025 | $185.85M | -25.1% |
| Q4 FY2025CQ3 2025 | Sep 30, 2025 | $188.86M | -17.9% |
| Q3 FY2025CQ2 2025 | Jun 30, 2025 | $204.11M | -32.0% |
| Q1 FY2025CQ4 2024 | Dec 31, 2024 | $216.69M | -35.7% |
| Q4 FY2024CQ3 2024 | Sep 30, 2024 | $248.19M | -32.9% |
| Q3 FY2024CQ2 2024 | Jun 30, 2024 | $230.09M | -40.5% |
| Q2 FY2024CQ1 2024 | Mar 31, 2024 | $300.31M | +42.9% |
| Q1 FY2024CQ4 2023 | Dec 31, 2023 | $337.15M | +57.2% |
| Q4 FY2023CQ3 2023 | Sep 30, 2023 | $369.91M | +48.4% |
| Q3 FY2023CQ2 2023 | Jun 30, 2023 | $386.59M | +52.6% |
| Q2 FY2023CQ1 2023 | Mar 31, 2023 | $210.08M | -25.1% |
| Q1 FY2023CQ4 2022 | Dec 31, 2022 | $214.47M | -17.2% |
| Q4 FY2022CQ3 2022 | Sep 30, 2022 | $249.23M | +2.1% |
| Q3 FY2022CQ2 2022 | Jun 30, 2022 | $253.29M | -1.4% |
| Q2 FY2022CQ1 2022 | Mar 31, 2022 | $280.33M | -25.4% |
| Q1 FY2022CQ4 2021 | Dec 31, 2021 | $259.05M | -32.9% |
| Q4 FY2021CQ3 2021 | Sep 30, 2021 | $244.00M | -36.9% |
| Q3 FY2021CQ2 2021 | Jun 30, 2021 | $256.82M | -30.6% |
| Q2 FY2021CQ1 2021 | Mar 31, 2021 | $375.95M | +5.8% |
| Q1 FY2021CQ4 2020 | Dec 31, 2020 | $386.20M | +3.3% |
| Q4 FY2020CQ3 2020 | Sep 30, 2020 | $386.65M | +15.3% |
| Q3 FY2020CQ2 2020 | Jun 30, 2020 | $370.00M | -4.9% |
| Q2 FY2020CQ1 2020 | Mar 31, 2020 | $355.26M | -4.0% |
| Q1 FY2020CQ4 2019 | Dec 31, 2019 | $373.79M | +8.1% |
| Q4 FY2019CQ3 2019 | Sep 30, 2019 | $335.24M | +8.6% |
| Q3 FY2019CQ2 2019 | Jun 30, 2019 | $389.25M | +816.4% |
| Q2 FY2019CQ1 2019 | Mar 31, 2019 | $370.16M | +453.1% |
| Q1 FY2019CQ4 2018 | Dec 31, 2018 | $345.79M | +408.1% |
| Q4 FY2018CQ3 2018 | Sep 30, 2018 | $308.73M | +38.0% |
| Q3 FY2018CQ2 2018 | Jun 30, 2018 | $42.48M | +90.8% |
| Q2 FY2018CQ1 2018 | Mar 31, 2018 | $66.93M | +248.4% |
| Q1 FY2018CQ4 2017 | Dec 31, 2017 | $68.05M | +230.1% |
| Q4 FY2017CQ3 2017 | Sep 30, 2017 | $223.67M | +1249.3% |
| Q3 FY2017CQ2 2017 | Jun 30, 2017 | $22.26M | -89.8% |
| Q2 FY2017CQ1 2017 | Mar 31, 2017 | $19.21M | – |
| Q1 FY2017CQ4 2016 | Dec 31, 2016 | $20.62M | – |
| Q4 FY2016CQ3 2016 | Sep 30, 2016 | $16.58M | – |
| Q3 FY2016CQ2 2016 | Jun 30, 2016 | $218.47M | – |
See a number that looks wrong?